8-K: MetaVia Unveils Promising Obesity, MASH Drug Data

MetaVia Inc. released an updated corporate presentation highlighting positive Phase 1 data for its obesity drug DA-1726 and Phase 2a top-line results for its MASH treatment DA-1241.

Summary

• DA-1726, a novel GLP1R/GCGR Dual Agonist for obesity, showed strong weight loss in Phase 1 Part 2 (32 mg dose), with a maximum reduction of -6.3% (15.4 lbs) and a mean reduction of -4.3% at Day 26.
• DA-1726 also demonstrated significant reductions in fasted glucose (mean -5.3 mg/dL, max -18 mg/dL at Day 26) and waist circumference (mean -4 cm or 1.6in, max -10 cm or 3.9in at Day 33).
• Safety data for DA-1726 indicated no treatment-related discontinuations, with most GI-related adverse events being mild, occurring after the first dose, and resolving within 24 hours.
• DA-1241, an orally available GPR119 Agonist for MASH, met its Phase 2a primary endpoint, showing direct hepatic effects and significant reductions in HbA1C compared to placebo at 100 mg dosing at Week 16.
• The company reported a cash balance of $17.6 million as of June 30, 2025, with no debt.
• Major shareholders include Dong-A ST Co., Ltd. (41% common stock) and Dong-A Socio Holdings Co., Ltd. (39% common stock).

Sentiment

Score: 8

Explanation: The filing presents highly positive clinical trial results for both lead drug candidates, DA-1726 and DA-1241, highlighting strong efficacy and favorable safety profiles, with claims of potential 'best-in-class' attributes. The company also outlines clear near-term milestones, indicating proactive development. While cash on hand is noted, the overall tone and data are very optimistic regarding future value creation.

Positives

• DA-1726's Phase 1 results demonstrated strong weight loss efficacy (max -6.3% / 15.4 lbs, mean -4.3% at Day 26) and a favorable safety profile with no treatment-related discontinuations.
• DA-1726 showed significant reductions in fasted glucose (mean -5.3 mg/dL, max -18 mg/dL) and waist circumference (mean -4 cm, max -10 cm), suggesting potential best-in-class efficacy for a GLP-1R/GCGR dual agonist.
• DA-1241 met its Phase 2a primary endpoint for MASH, indicating direct hepatic effects and significant HbA1C reductions, supporting its potential as a MASH treatment.
• The company has outlined multiple near-term milestones for both drug candidates, aiming to increase shareholder value through continued clinical development.
• Strong institutional backing from Dong-A ST Co., Ltd. (41%) and Dong-A Socio Holdings Co., Ltd. (39%) provides a stable ownership base.

Negatives

• Some GI-related adverse events (vomiting, nausea, constipation, abdominal distension) were reported with DA-1726, though generally mild and transient.
• The cash balance of $17.6 million as of June 30, 2025, may require future capital raises to fund extensive ongoing and planned clinical trials and commercialization efforts.

Risks

• Ability to execute commercial strategy.
• Sufficiency of existing cash on hand to fund operations.
• Timeline for regulatory submissions, regulatory steps, and potential regulatory approval of current and future product candidates.
• Ability to realize the benefits of the license agreement with Dong-A ST Co., Ltd., including the impact on future financial and operating results.
• Ability to integrate current and future product candidates into the business in a timely and cost-efficient manner.
• Cooperation of contract manufacturers, clinical study partners, and others involved in the development of current and future product candidates.
• Ability to initiate clinical trials on a timely basis and recruit subjects for clinical trials.
• Costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement.
• Changes in applicable laws or regulations.
• Effects of changes to the stock price on the terms of the license agreement and any future fundraising.
• Actual events or results may differ materially from forward-looking statements.

Future Outlook

The company plans to meet with the FDA in H2 2025 for DA-1241. For DA-1726, Q4 2025 will see additional SAD/MAD data, followed by a Phase 2a IND Amendment in Q1 2026, and Phase 2a initiation in Q2 2026, with 12-week interim data readout expected in H2 2026. The company is actively seeking combination/licensing partners for DA-1241.

Management Comments

• DA-1726 showed best-in-class potential for obesity with T2D / MASH, with strong weight loss and potential best-in-class glucose control and safety profile.
• DA-1241 will be actively seeking for combination/licensing partner.
• DA-1726's early satiety adverse event suggests greater weight loss may be seen in longer duration studies, further suggesting glucagon may have been the weight loss driver during the first 2 weeks.

Industry Context

The cardiometabolic disease market, particularly for obesity and MASH, is highly competitive and rapidly evolving, with significant recent M&A and licensing activities involving major pharmaceutical players like Novo Nordisk, AbbVie, Roche, and Lilly. MetaVia's dual agonist approach for obesity (DA-1726) and GPR119 agonist for MASH (DA-1241) positions it within a high-growth segment, aiming to differentiate through safety, tolerability, and efficacy profiles compared to existing and pipeline competitors.

Comparison to Industry Standards

• DA-1726's Phase 1 MAD (32mg, 4 weeks, no titration) showed 6.3% max weight loss and 4.3% mean weight loss, which compares favorably to other GLP-1R/GCGR agonists like Pemvidutide (10.3% at 12 weeks, 1.8mg, no titration), Mazdutide (9.8% at 12 weeks, 9mg), and Survodutide (5.79% at 6 weeks, titration to 0.45mg), considering the shorter duration of MetaVia's study.
• DA-1726's safety profile, with no treatment-related discontinuations and mild GI AEs, appears competitive, especially compared to Pemvidutide (72.8% mild/moderate vomiting, 91% mild/moderate nausea) and Tirzepatide (6.2% discontinuations for 15mg in Phase 3).
• DA-1726's glucose lowering (mean -5.3 mg/dL, max -18 mg/dL at Day 26) and waist circumference reduction (mean -4 cm, max -10 cm at Day 33) suggest potential best-in-class for GLP-1R/GCGR dual agonists.
• Preclinical data showed DA-1726 demonstrated superior body fat mass reduction and lean body mass preservation compared to Survodutide in HF-DIO mice, supporting its differentiation.
• DA-1241's direct hepatic effects and significant HbA1C reductions in Phase 2a for MASH position it as a promising candidate in a field with high unmet medical need, though direct comparative clinical data to other MASH drugs was not detailed in the filing beyond preclinical comparisons to semaglutide.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through positive clinical trial outcomes and future milestones, balanced by potential dilution from future fundraising.
• Patients (Obesity/MASH): Potential for new, effective, and well-tolerated treatment options for significant cardiometabolic diseases.
• Investment Professionals: Provides updated, positive clinical data for valuation and investment decision-making.
• Regulatory Authorities: Ongoing engagement with the FDA for drug development and potential approvals.

Next Steps

• DA-1726: Ongoing 4+4-week 48 mg dose cohort to explore the non-titrated maximum tolerated dose.
• DA-1726: Q4 2025 Phase 1 Additional SAD/MAD data to explore maximum tolerated dose.
• DA-1726: Q1 2026 Phase 2a IND Amendment.
• DA-1726: Q2 2026 Phase 2a Initiation.
• DA-1726: H2 2026 Phase 2a 12-week Interim Data Readout.
• DA-1241: H2 2025 Meeting with FDA.
• DA-1241: Actively seeking combination/licensing partners.
• DA-1241: Other exploratory endpoints including MRI-PDFF to be released at major medical conferences.

Key Dates

Recommendation

The filing presents compelling Phase 1 data for DA-1726 in obesity, demonstrating significant weight loss, glucose reduction, and waist circumference decrease with a favorable safety profile, positioning it as a potential best-in-class GLP-1R/GCGR dual agonist. Additionally, DA-1241's Phase 2a top-line results for MASH met its primary endpoint and showed significant HbA1C reductions. These strong clinical outcomes, coupled with a clear pipeline of near-term milestones and the company's focus on high-demand cardiometabolic diseases, suggest significant upside potential. While the cash balance is noted, the positive clinical advancements outweigh immediate financial concerns for a growth-oriented biotech investment, making it an attractive opportunity for seasoned investors.

Keywords

Biotech, Obesity, MASH, Cardiometabolic Diseases, GLP-1R/GCGR Agonist, GPR119 Agonist, Clinical Trials, Drug Development, Pharmaceutical